The purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.
Name: Panitumumab
Description: 6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicityType: DrugPanitumumab
Description: progression of disease within 2 months from registration according to RECIST criteria, and death for any cause within 2 months from registration
Measure: number of patients alive and without disease progression Time: 2 monthsDescription: Response assessed per patients at weeks 8,16,24,32,40 and every 3 months thereafter, using RECIST criteria
Measure: response rate Time: up to 40 weeksDescription: worst grade toxicity (according to Common Terminology Criteria for Adverse Events version 3) per patient
Measure: worst grade toxicity per patient Time: every 2 weeks for up to 6 monthsDescription: exploratory analysis of tumor-tissue for biological or genomic determinants of outcome of BRAF and P13K mutation status, EGFR and PTEN expression status
Measure: gene expression on tumor tissue Time: one yearSingle Group Assignment
There is one SNP
exploratory analysis of tumor-tissue for biological or genomic determinants of outcome of BRAF and P13K mutation status, EGFR and PTEN expression status. --- P13K ---